Sugammadex and Time to Extubation in Ophthalmic Surgery

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

262 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-08-01

Study Completion Date

2023-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is to invastigate if patients treated with sugammadex compared to neostigmine/atropine would be extubate faster upon emergence of anesthesia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparison of Sugammadex Administered at 1-2 Post Tetanic Counts (PTCs) or Better With Neostigmine Administered as Per Standard of Care to Reverse Rocuronium-Induced Neuromuscular Blockade in Adults Undergoing Elective Open Abdominal Procedure (19.4.334) (P05774)

NCT00675792

Anesthesia

COMPLETED PHASE3

The Study of Different Sedative Medications in Monitored Anesthesia Care During Eye Surgery With Local Anesthesia

NCT04018703

Balanced Anesthesia Adjuvants,Anesthesia

UNKNOWN NA

Comparison of 2.0 mg/kg Sugammadex and Neostigmine at Reappearance of T2 in Chinese and European Subjects (Study 19.4.324)(P05768AM1)(COMPLETED)

NCT00825812

Anesthesia, General Neuromuscular Blockade

COMPLETED PHASE3

Effectiveness on Smooth Extubation According to the Administration Time of Sugammadex

NCT05751603

Sugammadex Extubation Smooth Emergence

NOT_YET_RECRUITING NA

The Clinical Effect of Sugammadex Sodium (Domestic) for Antagonizing Neuromuscular Blockade After Thoracic Surgery

NCT06334562

Neuromuscular Blockade

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a retrospective case-control study including patients aged 18 years or older who underwent ophthalmic surgeries under general anesthesia with tracheal intubation between 2020 and 2022. Patients who received rocuronium as the sole neuromuscular blocking agent and were maintained with sevoflurane or desflurane and intravenous fentanyl were included. Based on the choice of reversal agent for neuromuscular blockade, patients were divided into two groups: the sugammadex group or the neostigmine group. Patients who underwent emergency surgery or combined surgeries with other specialties were excluded. Patient characteristics, including age, gender, ASA classification, weight, and height, were collected. Anesthesia-related medications were recorded. The time points of anesthesia induction, start and end of surgery, reversal agent administration, and tracheal extubation were documented.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

General Anesthesia Using Endotracheal Intubation Ophthalmologic Surgical Procedure Sugammadex Neostigmine Extubation Readiness

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

sugammadex

those who use sugammadex for reversal of neuromuscular blockade

sugammadex

Intervention Type DRUG

sugammadex used for neuromuscular reversal

neostigmine

those who use neostigmine/atroping for reversal of neuromuscular blockade

Neostigmine + Atropine

Intervention Type DRUG

Neostigmine and Atropine used for neuromuscular reversal

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

sugammadex

sugammadex used for neuromuscular reversal

Intervention Type DRUG

Neostigmine + Atropine

Neostigmine and Atropine used for neuromuscular reversal

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

aged 18 years or older ophthalmic surgeries under general anesthesia with tracheal intubation between 2020 and 2022 received rocuronium as the sole neuromuscular blocking agent maintained with sevoflurane or desflurane and intravenous fentanyl